The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

StocksUpdated×2•Originally published 4 May 2026•Updated 5 May 2026•

1 min read

Securities Class Action Lawsuits Filed Against ImmunityBio and Gemini Space Station

Key Facts

1ImmunityBio faces a class action lawsuit after an FDA warning letter regarding misleading promotion of the drug Anktiva caused IBRX shares to drop 21.1%.

2A May 18, 2026 deadline has been set for investors to seek lead plaintiff status in a securities fraud class action against Gemini Space Station.

ImmunityBio and Gemini Space Station are facing securities class action lawsuits alleging investor misrepresentation, with the crisis resulting in a $2 billion loss in market capitalization. A lead plaintiff deadline of May 26, 2026, has been established for the lawsuit against ImmunityBio (IBRX), with the law firm Hagens Berman handling shareholder updates. The legal action alleges that misleading statements were made regarding the drug Anktiva, following a 21.1% drop in IBRX shares triggered by an FDA warning. Meanwhile, Gemini Space Station investors face a May 18, 2026, deadline regarding IPO-related fraud claims. These developments underscore the heightened regulatory scrutiny on biotechnology and emerging tech firms regarding the accuracy of corporate disclosures.

29 days ago

Version History

Version 229 days ago

What changed: Added details regarding the $2 billion market capitalization loss and identified Hagens Berman as the law firm handling shareholder updates.

Version 130 days ago

What changed: Updated to include the specific lead plaintiff deadline for ImmunityBio (May 26, 2026), the identified class period, and the naming of the CEO in the allegations.